Navigation Links
China Kangtai Cactus Biotech Retains Hawk Associates for Investor Relations Services

HARBIN, China, July 6 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus Biotech Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of cactus-based consumer products in China, announced today that it has retained the services of Hawk Associates for strategic investor relations. Information about China Kangtai will be available through the Hawk Associates website at: , featuring company updates, investor information and live financial feeds.

China Kangtai CEO Jinjiang Wang said, "We look forward to working with Hawk Associate, which has been providing comprehensive strategic IR services for 14 years in their roles as trusted advisors. We believe Hawk Associates is one of the premier investor relations firms that effectively helps companies successfully communicate their stories to the investment community. The branding and investor relations expertise that Hawk provides will be essential in assisting management in showcasing the true value of our company."

Hawk Associates CEO Frank Hawkins said, "As the dominant producer with 60% market share of China's edible cactus production, China Kangtai is a major beneficiary of growing Chinese demand for health and wellness products. In China, cactus products are traditionally used for treatment for health issues such as diabetes, adiposity, constipation, cholesterol, high blood pressure, low immunity and skin disorders. This is a unique company in an unsaturated industry. With the company's recent acquisition in March, Kangtai is seeking to increase its production capabilities in an effort to enhance its overall growth. We are thrilled to be able to help Kangtai tell its story to the investment community to strengthen its long-term valuation."

About China Kangtai Cactus Biotech, Inc.

China Kangtai Cactus Biotech Inc. is a leading grower, developer, producer and marketer of cactus-derived products, including nutraceuticals, nutritional food and drinks, and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12 in a variety of product categories. China Kangtai's high-quality "green" products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 12 provinces and 2 municipalities. For more information, please contact: Chengzhi Wang, General Manager of China Kangtai Cactus Biotech, Inc. Email:

For more investor-related questions, contact Susan Zhou, Hawk Associates, at 305-451-1888. To subscribe to future releases via e-mail alert, visit .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE China Kangtai Cactus Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. RainEarth (RNER) Continues to Expand its Marketing Force in China
2. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
3. China-Biotics, Inc. to Join Russell 3000 Index
4. NeoStem Signs Agreement with Shanghai Corporation to Develop A Stem Cell Collection and Treatment Network in Shanghai, Taiwan and Other Targeted China Provinces
5. China Biologic Products Closes the $9.6 Million Private Placement
6. China Biologic Products Enters Into Private Placement Agreements to Raise $9.6 Million
7. Chinas Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation
8. Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
9. China-Biotics, Inc. to Attend Digestive Disease Week 2009
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
Post Your Comments:
(Date:10/13/2015)... and TORONTO , Oct. 13, 2015 ... announced that it has entered into a non-binding Letter of ... private Israeli company that has developed a proprietary cooling technology ... to varicoceles. the United States ... between the ages of 25 and 44 diagnosed as infertile.  ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed ... growing clinical data solutions business. , Jeff Parr has spent the past decade providing ... Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. He is ...
(Date:10/13/2015)... ... ... Proove Biosciences, a commercial and research leader ... Medicine of the University of Southern California (USC) Pain Center to study ... Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one of ...
(Date:10/13/2015)... the United States , Canada ... 14% of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison ... ("AstraZeneca") have completed enrolment in a global Phase II study of ...
Breaking Biology Technology:
(Date:10/6/2015)... MATEO, Calif. , Oct. 6, 2015 /PRNewswire/ ... company, today announced enhancements to its software portfolio ... expression analysis kit for differential expression in eukaryotes. ... Platform, which is a cloud-based genomic analysis solution ... advance scientific discovery from next-generation sequencing efforts. ...
(Date:9/30/2015)... SACRAMENTO, Calif. , Sept. 30, 2015  With ... and the number of new SCIs estimated to reach ... like Southern California Resource Services for Independent Living ... 28 ILCs in California opening ... a range of programs and services, notably assistive technology ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to be ... its product to market. The official announcement was recently made ... event in San Francisco , where ... powered by IBM Watson. "It is both an ... 100 companies to bring to market the cognitive power of ...
Breaking Biology News(10 mins):